Display options
Share it on

Frontline Gastroenterol. 2021 Mar 11;13(1):86-88. doi: 10.1136/flgastro-2021-101818. eCollection 2022.

Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections.

Frontline gastroenterology

Rooshi Nathwani, David Kockerling, Benjamin H Mullish, Alexander Cole, Maud Lemoine, Charalambos Gustav Antoniades, Mark R Thursz, Ameet Dhar

Affiliations

  1. Division of Digestive Diseases, Imperial College London, London, UK.
  2. Department of Metabolism, Digestion and Reproduction, Imperial College Healthcare NHS Trust, London, UK.

PMID: 34970431 PMCID: PMC8666853 DOI: 10.1136/flgastro-2021-101818

[No abstract available.]

Keywords: bacterial infection; cirrhosis; portal hypertension

Conflict of interest statement

Competing interests: None declared.

References

  1. J Hepatol. 2014 Jun;60(6):1310-24 - PubMed
  2. Hepatology. 2012 Dec;56(6):2328-35 - PubMed
  3. Chest. 2003 Sep;124(3):1016-20 - PubMed
  4. J Hepatol. 2014 Dec;61(6):1385-96 - PubMed
  5. Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5 - PubMed
  6. Hepatology. 2014 Jul;60(1):250-6 - PubMed
  7. Gut. 2021 Sep;70(9):1758-1767 - PubMed

Publication Types